Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression.
about
Clinical potential of pacritinib in the treatment of myelofibrosisConstitutive expression of the FK506 binding protein 51 (FKBP51) in bone marrow cells and megakaryocytes derived from idiopathic myelofibrosis and non-neoplastic haematopoiesis.Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivationFKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A.Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation.Transcriptome Analysis of Monozygotic Twin Brothers with Childhood Primary Myelofibrosis.JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.The emerging role of large immunophilin FK506 binding protein 51 in cancerSTAT signaling in the pathogenesis and treatment of myeloid malignancies.Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine.FKBP51 protects 661w cell culture from staurosporine-induced apoptosis.Primary myelofibrosis and the "bad seeds in bad soil" concept.Hsp90-binding immunophilin FKBP51 forms complexes with hTERT enhancing telomerase activity.The prospect of FKBP51 as a drug target.Validating the Sensitivity of High-Resolution Melting Analysis for JAK2 V617F Mutation in the Clinical Setting.
P2860
Q26796450-0D0C6163-A5AF-4C8C-97CC-38488A2D7FFCQ33201759-9D40718D-D163-456D-B249-C8810E54B85EQ33412693-2FC34E6B-FA41-4EF6-8F89-B7EC0206E91BQ34580343-32BEDF04-21F4-4BAF-A901-75B3391EF6E8Q36402468-90C8F036-32F6-4CE3-BE2B-11F94674E7F6Q37683345-2796FCF5-5D1F-42E5-A894-447DB7843485Q37810100-AD5A0582-6EBB-47ED-9BF9-DCAC43E0E5E2Q37833893-CAEC7755-56FE-4182-96DE-2CF95C50E030Q37956712-10F1C262-69CB-4AE7-A0F7-DC58FFCF399BQ38140880-F5617C71-1F98-4461-B53A-180741572D94Q39202346-60C2CA12-670F-4664-950D-56D7256ED170Q39535549-5E1D9690-9789-41DA-BC69-1A9EA328AC69Q41838687-D344A5B5-6A61-4844-A9A4-565EE3E2F2FAQ41882137-1CF3375E-E005-46D5-82F8-6A887A40FD96Q48682440-3329A446-0321-4AEA-AB95-D0AF3DB17E8EQ51746620-28A3BB1D-AA8F-46D5-8E66-0233B61E6D2F
P2860
Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Spontaneous STAT5 activation i ...... ip with FKBP51 overexpression.
@en
Spontaneous STAT5 activation i ...... ip with FKBP51 overexpression.
@nl
type
label
Spontaneous STAT5 activation i ...... ip with FKBP51 overexpression.
@en
Spontaneous STAT5 activation i ...... ip with FKBP51 overexpression.
@nl
prefLabel
Spontaneous STAT5 activation i ...... ip with FKBP51 overexpression.
@en
Spontaneous STAT5 activation i ...... ip with FKBP51 overexpression.
@nl
P2093
P1476
Spontaneous STAT5 activation i ...... hip with FKBP51 overexpression
@en
P2093
Benoit Blanchet
Emiko Komura
Frédéric Larbret
Hédia Chagraoui
Jérome Larghero
Michel Tulliez
Najet Debili
Stéphane Giraudier
Véronique Mansat de Mas
P304
P356
10.1016/S0301-472X(03)00085-7
P577
2003-07-01T00:00:00Z